Musa Yılmaz

8.2k citations

149 papers · 2.0k indexed · h-index 25

Hematology top 0.5%
- Acute Myeloid Leukemia Research 88
- Chronic Myeloid Leukemia Treatments 65
- Hematopoietic Stem Cell Transplantation 13
- Multiple Myeloma Research and Treatments 12
Genetics top 2%
- Chronic Lymphocytic Leukemia Research 48
- Myeloproliferative Neoplasms: Diagnosis and Treatment 30
Public Health, Environmental and Occupational Health top 2%
- Acute Lymphoblastic Leukemia research 40
Oncology top 5%
Rheumatology top 5%
- Eosinophilic Disorders and Syndromes 18

Co-authors: Hagop M. Kantarjian Farhad Ravandi Elias Jabbour Nicholas J. Short Tapan M. Kadia Naval Daver Gautam Borthakur Marina Konopleva
Cited by: Hematology Genetics Public Health, Environmental and Occupational Health
Journals: Journal of Clinical Oncology (18 papers)SHILAP Revista de lepidopterología (1 paper)Blood (50 papers)
Partner nations: United States Türkiye Georgia

In The Last Decade

Musa Yılmaz

131 papers receiving 2.0k citations

Peers

Countries citing papers authored by Musa Yılmaz

Since Specialization

Citations

This map shows the geographic impact of Musa Yılmaz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Musa Yılmaz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Musa Yılmaz more than expected).

Fields of papers citing papers by Musa Yılmaz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Musa Yılmaz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Musa Yılmaz. The network helps show where Musa Yılmaz may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Musa Yılmaz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Musa Yılmaz Line = papers co-authored together Musa Yılmaz links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Mortality and relapse dynamics in AML after three years of complete remission Leukemia & lymphoma ·Samuel Urrutia,Wei‐Ying Jen,Koji Sasaki,Peter H. Wiernik,Tapan M. Kadia,Naval Daver,Courtney D. DiNardo,Guillermo Garcia-Manero,Elias Jabbour,Nicholas J. Short,Ghayas C. Issa,Farhad Ravandi,Musa Yılmaz	2025	0
2	Hyper‐CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome‐Negative B‐Cell Acute Lymphoblastic Leukemia American Journal of Hematology ·Hagop M. Kantarjian,Nicholas J. Short,Nitin Jain,Fadi Haddad,Tapan M. Kadia,Musa Yılmaz,Alessandra Ferrajoli,Koji Sasaki,Yesid Alvarado,Naveen Pemmaraju,Jayastu Senapati,Rebecca Garris,Farhad Ravandi,Elias Jabbour	2025	6
3	Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome Leukemia Research ·Julie Braish,Guillermo Montalban‐Bravo,Farhad Ravandi,Nicholas J. Short,Tapan Kadia,Maro Ohanian,Kelly S. Chien,Lucia Masárová,Koji Sasaki,Musa Yılmaz,Sanam Logahvi,Naval Daver,Gautam Borthakur,Elias Jabbour,Heather Schneider,L. Michael Romero,H. Kantarjian,Guillermo Garcia‐Manero	2025	1
4	Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up Blood ·Jayastu Senapati,H. Kantarjian,Edward Ayoub,Akhil Jain,Tapan M. Kadia,Courtney D. DiNardo,Naval Daver,Fadi Haddad,Naveen Pemmaraju,Nicholas J. Short,Maro Ohanian,Musa Yılmaz,Keyur P. Patel,Mark Brandt,Sherry Pierce,Guillermo Garcia‐Manero,Farhad Ravandi,Gautam Borthakur	2024	1
5	Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia Clinical Lymphoma Myeloma & Leukemia ·Jason Yeh,Oren Pasvolsky,Rima M. Saliba,Bradley Figgins,Christopher Wang,Zhou Fang,Sairah Ahmed,Musa Yılmaz,Naval Daver,Farhad Ravandi,Courtney D. DiNardo,Nicholas J. Short,Tapan M. Kadia,Gheath Alatrash,May Daher,David Marin Costa,Uday Popat,Richard Champlin,Elizabeth J. Shpall,Betül Oran	2024	2
6	FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML. Journal of Clinical Oncology ·Wei‐Ying Jen,Koichi Takahashi,Sanam Loghavi,Tapan M. Kadia,Naval Daver,Lianchun Xiao,Nicholas J. Short,Gautam Borthakur,Ghayas C. Issa,Naveen Pemmaraju,Patrick K. Reville,Guillermo Montalban‐Bravo,Musa Yılmaz,Guillermo Garcia‐Manero,Farhad Ravandi‐Kashani,Marina Konopleva,Jillian Mullin,Sherry Pierce,Hagop M. Kantarjian,Courtney D. DiNardo	2024	8
7	Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression British Journal of Haematology ·Wei‐Ying Jen,Koji Sasaki,Sanam Loghavi,Sa A. Wang,Wei Qiao,Gautam Borthakur,Farhad Ravandi,Tapan M. Kadia,Ghayas C. Issa,Nicholas J. Short,Musa Yılmaz,Naval Daver,Courtney D. DiNardo	2024	3
8	Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results Blood ·Georgina Gener‐Ricos,Gautam Borthakur,Koji Sasaki,Guilin Tang,Guillermo Montalban‐Bravo,Elias Jabbour,Maro Ohanian,Musa Yılmaz,Fadi Haddad,Kelly S. Chien,Jo Ishizawa,Nicholas J. Short,Abhishek Maiti,Mahesh Swaminathan,Guillermo Garcia‐Manero,Naval Daver,Courtney D. DiNardo,Farhad Ravandi,Tapan M. Kadia	2023	0
9	The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors American Journal of Hematology ·Elias Jabbour,Koji Sasaki,Fadi Haddad,Ghayas C. Issa,Guillermo Garcia‐Manero,Tapan M. Kadia,Nitin Jain,Musa Yılmaz,Courtney D. DiNardo,Keyur P. Patel,Rashmi Kanagal‐Shamanna,Richard Champlin,Issa F. Khouri,Sara Dellasala,Sherry Pierce,Hagop M. Kantarjian	2023	15
10	Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation Blood Advances ·Nicholas J. Short,Faustine Ong,Farhad Ravandi,Graciela M. Nogueras‐González,Tapan M. Kadia,Naval Daver,Courtney D. DiNardo,Marina Konopleva,Gautam Borthakur,Betül Oran,Gheath Alatrash,Rohtesh S. Mehta,Elias Jabbour,Musa Yılmaz,Ghayas C. Issa,Abhishek Maiti,Richard E. Champlin,Hagop M. Kantarjian,Elizabeth J. Shpall,Uday Popat	2023	13
11	Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax Blood Advances ·Álex Bataller,Alexandre Bazinet,Courtney D. DiNardo,Abhishek Maiti,Gautam Borthakur,Naval Daver,Nicholas J. Short,Elias Jabbour,Ghayas C. Issa,Naveen Pemmaraju,Musa Yılmaz,Guillermo Montalban‐Bravo,Koichi Takahashi,Sanam Loghavi,Guillermo Garcia‐Manero,Farhad Ravandi,Hagop M. Kantarjian,Tapan M. Kadia	2023	36
12	Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients Leukemia & lymphoma ·Wei‐Ying Jen,Koji Sasaki,Caitlin R. Rausch,Courtney D. DiNardo,Tapan M. Kadia,Musa Yılmaz,Gautam Borthakur,Yesid Alvarado,David McCue,Deborah McCue,Hagop M. Kantarjian,Farhad Ravandi	2023	6
13	Ultrasensitive NGS MRD assessment in Ph+ ALL : Prognostic impact and correlation with RT‐PCR for BCR::ABL1 American Journal of Hematology ·Nicholas J. Short,Elias Jabbour,Walid Macaron,Farhad Ravandi,Nitin Jain,Rashmi Kanagal‐Shamanna,Keyur P. Patel,Sanam Loghavi,Fadi Haddad,Musa Yılmaz,Ghayas C. Issa,Partow Kebriaei,Steven M. Kornblau,Sarah Pelletier,Wilmer Flores,Jairo Matthews,Rebecca Garris,Hagop M. Kantarjian	2023	37
14	Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia SHILAP Revista de lepidopterología ·Kyaw Zaw Hein,Nicholas J. Short,Elias Jabbour,Musa Yılmaz	2022	11
15	Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes American Journal of Hematology ·Daniel Rivera,Kunhwa Kim,Rashmi Kanagal‐Shamanna,Gautam Borthakur,Guillermo Montalban‐Bravo,Naval Daver,Courtney D. DiNardo,Nicholas J. Short,Musa Yılmaz,Naveen Pemmaraju,Koichi Takahashi,Elias Jabbour,Sherry Pierce,Marina Konopleva,Kapil N. Bhalla,Guillermo Garcia‐Manero,Farhad Ravandi,Hagop M. Kantarjian,Tapan M. Kadia	2022	17
16	Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification American Journal of Hematology ·Patrick K. Reville,Koji Sasaki,Hagop M. Kantarjian,Naval Daver,Musa Yılmaz,Courtney D. DiNardo,Nicholas J. Short,Gautam Borthakur,Naveen Pemmaraju,Rohtesh S. Mehta,Sherry Pierce,Sergej Konoplev,Joseph D. Khoury,Guillermo Garcia‐Manero,Marina Konopleva,Elias Jabbour,Farhad Ravandi,Tapan M. Kadia	2022	16
17	Two Cases of Possible Familial Chronic Myeloid Leukemia in a Family with Extensive History of Cancer Acta Haematologica ·Marisa J.L. Aitken,Christopher B. Benton,Ghayas C. Issa,Koji Sasaki,Musa Yılmaz,Nicholas J. Short	2021	5
18	Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis Cancer ·Elias Jabbour,Koji Sasaki,Farhad Ravandi,Nicholas J. Short,Guillermo Garcia‐Manero,Naval Daver,Tapan M. Kadia,Marina Konopleva,Nitin Jain,Jörge E. Cortes,Ghayas C. Issa,Jovitta Jacob,Monica Kwari,Philip A. Thompson,Rebecca Garris,Naveen Pemmaraju,Musa Yılmaz,Susan O’Brien,Hagop M. Kantarjian	2019	66
19	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3‐internal tandem duplication mutation–positive acute myeloid leukemia Cancer ·Koji Sasaki,Hagop M. Kantarjian,Tapan M. Kadia,Keyur P. Patel,Sanam Loghavi,Guillermo Garcia‐Manero,Elias Jabbour,Courtney D. DiNardo,Naveen Pemmaraju,Naval Daver,Iman Abou Dalle,Nicholas J. Short,Musa Yılmaz,Prithviraj Bose,Kiran Naqvi,Sherry Pierce,Fevzi Yalniz,Jörge E. Cortes,Farhad Ravandi	2019	36
20	Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3 ‐internal tandem duplication genotypes Cancer ·Prajwal Boddu,Tapan M. Kadia,Guillermo Garcia‐Manero,Jörge E. Cortes,Mansour Alfayez,Gautam Borthakur,Marina Konopleva,Elias Jabbour,Naval Daver,Courtney D. DiNardo,Kiran Naqvi,Musa Yılmaz,Nicholas J. Short,Sherry Pierce,Hagop M. Kantarjian,Farhad Ravandi	2018	37

About Musa Yılmaz

Musa Yılmaz is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health, having authored 149 papers that have together received 2.0k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (88 papers), Chronic Myeloid Leukemia Treatments (65 papers), Chronic Lymphocytic Leukemia Research (48 papers), Acute Lymphoblastic Leukemia research (40 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (30 papers), Eosinophilic Disorders and Syndromes (18 papers), Hematopoietic Stem Cell Transplantation (13 papers) and Multiple Myeloma Research and Treatments (12 papers). The work is most often cited by research in Hematology (1.5k citations), Genetics (596 citations) and Public Health, Environmental and Occupational Health (641 citations). Musa Yılmaz has collaborated with scholars based in United States, Türkiye and Georgia. Frequent co-authors include Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Nicholas J. Short, Tapan M. Kadia, Naval Daver, Gautam Borthakur, Marina Konopleva, Courtney D. DiNardo and Guillermo Garcia‐Manero. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact